Please login to the form below

Not currently logged in
Email:
Password:

Huntington's disease

This page shows the latest Huntington's disease news and features for those working in and with pharma, biotech and healthcare.

Teva’s weak pipeline hit by Tourette’s drug trial failure

Teva’s weak pipeline hit by Tourette’s drug trial failure

Deutetrabenazine is already approved as  Austedo for the treatment of movement disorder chorea in patients with Huntington’s disease and for tardive dyskinesia – a side effect of antipsychotic drugs – but Teva ... 110 and Otsuka’s

Latest news

More from news
Approximately 6 fully matching, plus 40 partially matching documents found.

Latest Intelligence

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    to learn from its own mistakes with therapies for Huntington’s disease and also haemophilia. ... Increasingly factored into this equation is competition from companies following Bluebird into beta thalassemia and sickle cell disease.

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    Two further candidates, AL003 for Alzheimer’s disease and AL004 for multiple degenerative disorders, are also set to enter clinical trials this year. ... Diseases include Alzheimer’s, dementia with Lewy bodies, frontotemporal dementia, as well as

  • Deal Watch October 2018

    Collaboration for. development. $760m. Enterome/. Takeda. EB8018 for Crohn’s disease and other gastrointestinal. ... Roche has an existing agreement with Ionis for IONIS‐HTTRx, an antisense drug for Huntington’s Disease, and the new deal is to

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    RG6042 (formerly named IONIS-HTTRx) is in development for Huntington’s disease. ... It’s hoped it could be a big step in treatment for the genetically-inherited and rare wasting disease.

  • Deal Watch May 2016 Deal Watch May 2016

    Teva's drug SD 809 for the treatment of Huntington's disease was part of the acquisition of Auspex at a cost of $3.5bn. ... disease late last year, Bayer announced another gene editing pact this month with ERS Genomics.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • uniQure appoints chief executive officer uniQure appoints chief executive officer

    This is an exciting time for uniQure, and I am fully committed to the company's success and the execution of our core strategic goals. ... for congestive heart failure and Huntington's disease into the clinic.”.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Use of biomarkers in marketing

    pathway.  . When we think of biomarkers, we usually imagine the detection of genetic disorders such as Huntington’s disease and Alzheimer’s; these are prognosis biomarkers. ... A crowded market of biologics treating a chronic disease with very

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

AI and genomics: a revolution in drug discovery and development
...
Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....

Infographics